Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment

por Wu, Yuan‐Kun (Aden), Tsai, Cheng‐Hsuan, Su, Mao‐Yuan, Chao, Chi‐Chao, Cheng, Mei‐Fang, Shun, Chia‐Tung, Hsieh, Sung‐Tsang, Lin, Yen‐Hung
Publicado 2022

Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study

por Tsai, Cheng-Hsuan, Chao, Chi-Chao, Hsieh, Sung-Tsang, Yu, An-Li, Wu, Yuan-Kun (Aden), Cheng, Mei-Fang, Lee, Ming-Jen, Chou, Chia-Hung, Shun, Chia-Tung, Hsueh, Hsueh-Wen, Jyh-Ming Juang, Jimmy, Tseng, Ping-Huei, Su, Mao-Yuan, Lin, Yen-Hung
Publicado 2023